Felix Biotechnology is building a Virus Design Platform using machine learning and A.I. to design custom phages (bacteria-specific viruses), to target and kill any kind of bacteria. Managing bacteria is a $550 billion dollar opportunity, and customers are demanding chemical-free, safe, effective, and green ways to target and eliminate bacteria. Goals for phage-use include skin care, alternatives to failing antibiotics, microbiome health, women’s health, oral care, agricultural plant and animal health, water contamination, and methane emissions. Our Virus Design Platform simplifies phage engineering, expands phage host-range, and mitigates evolution of phage-resistance in target bacteria. We use machine learning to inform DESIGN of virus genomes to enhance their usefulness as therapeutics; we BUILD viruses by printing/booting or engineering their DNA using CRISPR-Cas13a; and we TEST viruses using high throughput tools that create large datasets which relate phage genetics to behavior. Felix develops phages for other companies, to rapidly advance our tech, diversify risk and generate revenue quickly. Felix is the only company that can mine existing databases for printable viruses as raw material for its discovery pipeline, unlocking the power of novel phages to advance new applications, and to solve difficult problems in health and disease. Our generalized phage products are more rapid, less costly, and can reach more customers. Furthermore, our engineered products can have greater efficacy, while also securing stronger I.P. By engineering viruses that target any bacteria, Felix Biotechnology’s Virus Design Platform is poised to address our most difficult challenges in the current century.